Hua Medicine (Shanghai) Ltd. (HKG:2552)

Market Cap	2.06B
Revenue (ttm)	272.31M
Net Income (ttm)	-266.20M
Shares Out	983.66M
EPS (ttm)	-0.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,751,500
Average Volume	1,952,496
Open	2.040
Previous Close	2.060
Day's Range	2.040 - 2.120
52-Week Range	1.030 - 2.790
Beta	1.35
RSI	49.29
Earnings Date	May 29, 2025

About Hua Medicine (Shanghai)

Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic diseas...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2011
• Employees: 168
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2552

Financial Performance

In 2024, Hua Medicine (Shanghai)'s revenue was 255.89 million, an increase of 234.02% compared to the previous year's 76.61 million. Losses were -250.14 million, 18.4% more than in 2023.

Financial numbers in CNY